ELICIO THERAPEUTICS INC
Reported by Steward Partners Investment Advisory LLC
Reported 2,023 shares, unchanged from the prior quarter.
Reported value -63.4%; share count 0.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2023-06-30 | 14763 |
| 2023-09-30 | 13131 |
| 2023-12-31 | 12960 |
| 2024-03-31 | 11810 |
| 2024-06-30 | 6387 |
| 2024-09-30 | 7817 |
| 2024-12-31 | 7925 |
| 2025-03-31 | 9573 |
| 2025-06-30 | 11997 |
| 2025-09-30 | 17001 |
| 2025-12-31 | 12370 |
| 2026-03-31 | 21626 |
| 2026-06-30 | 7910 |
| 2026-09-30 | 3682 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Unchanged | 2,023 | 0 (0.0%) | < 0.01% | $3,682 | 2026-11-13 | |
| Q2 2026 | Unchanged | 2,023 | 0 (0.0%) | < 0.01% | $7,910 | 2026-08-13 | |
| Q1 2026 | Added | 2,023 | +469 (30.2%) | < 0.01% | $21,626 | 2026-05-08 | |
| Q4 2025 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $12,370 | 2026-02-12 | |
| Q3 2025 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $17,001 | 2025-11-12 | |
| Q2 2025 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $11,997 | 2025-08-12 | |
| Q1 2025 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $9,573 | 2025-05-13 | |
| Q4 2024 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $7,925 | 2025-02-06 | |
| Q3 2024 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $7,817 | 2024-11-14 | |
| Q2 2024 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $6,387 | 2024-08-08 | |
| Q1 2024 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $11,810 | 2024-05-15 | |
| Q4 2023 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $12,960 | 2024-02-12 | |
| Q3 2023 | Unchanged | 1,554 | 0 (0.0%) | < 0.01% | $13,131 | 2023-11-13 | |
| Q2 2023 | New | 1,554 | +1,554 (0.0%) | < 0.01% | $14,763 | 2023-08-14 |
Who else reported the position
72 managers reported ELICIO THERAPEUTICS INC for Q2 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| Knoll Capital Management LLC | Added | 1,211,957 | +581,042 | 2.21% | $4,738,751 | 6 qtrs |
| BlackRock Inc | Added | 766,005 | +715,408 | < 0.01% | $2,995,079 | 8 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 572,151 | +53,513 | < 0.01% | $2,237,110 | 2 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 311,354 | +176,190 | < 0.01% | $1,217,614 | 13 qtrs |
| STATE STREET CORPORATION | Added | 179,420 | +128,800 | < 0.01% | $701,532 | 10 qtrs |
| NORTHERN TRUST CORPORATION | Added | 130,162 | +70,428 | < 0.01% | $508,933 | 9 qtrs |
| Ikarian Capital LLC | New | 100,000 | +100,000 | 0.04% | $391,000 | 1 qtr |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New | 88,905 | +88,905 | < 0.01% | $347,619 | 1 qtr |
| VANGUARD FIDUCIARY TRUST CO | Added | 88,062 | +18,873 | < 0.01% | $344,322 | 2 qtrs |
| ALLIANCEBERNSTEIN L P | New | 81,280 | +81,280 | < 0.01% | $317,805 | 1 qtr |
Filing details and methodology As reported
- Report period
- June 30, 2026
- Filed
- August 13, 2026
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 0
- Shared
- 0
- None
- 2,023
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.